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Abstract 
The Ca2+ signal is essential in both hypoxia- and epidermal growth factor (EGF)-mediated 
epithelial to mesenchymal transition (EMT) in MDA-MB-468 breast cancer cells. This finding 
suggests that Ca2+-permeable ion channels participate in the induction of expression of some 
mesenchymal markers such as vimentin. However, the ion channels involved in vimentin 
expression induction have not been fully characterized. This work sought to define how 
differential modulation of the calcium signal effects the induction of vimentin and the Ca2+ 
influx pathways involved. We identified that the intracellular Ca2+ chelator EGTA-AM, 
cytochalasin D (a modulator of cytoskeletal dynamics and cell morphology) and the 
sarco/endoplasmic reticulum ATPase inhibitor thapsigargin are all inducers of vimentin in 
MDA-MB-468 breast cancer cells. EGTA-AM- and thapsigargin-mediated induction of 
vimentin expression in MDA-MB-468 cells involves store-operated Ca2+ entry, as evidenced 
by sensitivity to silencing of the molecular components of this pathway, STIM1 and ORAI1. 
In stark contrast, cytochalasin D-mediated vimentin induction was insensitive to silencing of 
ORAI1, despite sensitivity to silencing of its canonical activator the endoplasmic reticulum 
Ca2+ sensor STIM1. Cytochalasin D-mediated vimentin induction was, however, sensitive to 
silencing of another reported STIM1 target, TRPC1. Subsequent studies identified that EGTA-
AM-induced vimentin expression also partially involved a TRPC1-dependent pathway. These 
studies define a complex interplay between vimentin expression in this model and the specific 
Ca2+-permeable ion channels involved. The complexity in the engagement of different Ca2+ 
influx pathways that regulate vimentin induction are opportunities but also potential challenges 
in targeting Ca2+ signaling to block EMT in cancer cells. Our findings further highlight the 
need to identify potential indispensable ion channels that can regulate induction of specific 
mesenchymal markers via different stimuli.  
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Introduction 
The plasticity of cancer cells allows the acquisition of features that can contribute to disease 
progression [1]. In breast cancer, the conversion of epithelial cells to a more invasive and 
therapy-resistant phenotype can be the consequence of epithelial to mesenchymal transition 
(EMT) [2, 3]. Conditions within the tumor microenvironment, such as specific growth factors 
and hypoxia, are often inducers of EMT [1, 4, 5]. The conversion of some breast cancer cells 
to a more mesenchymal phenotype is associated with the loss of epithelial markers such as E-
cadherin and claudin 4 [1, 6]. EMT is also associated with acquisition of mesenchymal markers 
such as the transcription factors Twist, Zeb and Snail, and is linked to stemness via an increase 
in CD44 and/or a down regulation of CD24 cell adhesion molecule levels [7, 8]. In many 
models of breast cancer cells, EMT also results in a pronounced up-regulation of the 
intermediate filament protein vimentin, which is a regulator of cellular motility, adhesion and 
signaling [9]. The identification of regulators of EMT in breast cancer cells represents a new 
suite of drug targets for therapeutic intervention of metastatic progression and/or drug 
resistance [3, 10, 11]. 
 
Recently, studies have identified the remodeling of Ca2+ signaling and/or changes in the 
expression of components of Ca2+ transport as a consequence of EMT in cancer cells ([5, 12-
14] and reviewed in [15]). The Ca2+ signal itself is also a key regulator of the induction of EMT 
by some stimuli. For example, EMT induced by both epidermal growth factor (EGF) and 
hypoxia is inhibited by the suppression of Ca2+ signals by intracellular Ca2+ buffering using 
BAPTA-AM in MDA-MB-468 breast cancer cells [5]. Similarly, BAPTA-AM reduces EMT 
induced by acidity in PANC-1 and BxPC-3 pancreatic cancer cells [16] and by transforming 
growth factor (TGF)-β1 in A549 lung cancer cells [17]. These studies collectively place the 
Ca2+ signal as a vital cellular signal in the induction and/or maintenance of EMT. However, the 
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contribution of specific Ca2+ influx pathways to EMT induction is likely to be dependent on 
the broader cellular context, that is, the nature of the inducer and/or the type and features of the 
cancer cell line under investigation. For example, the plasma membrane localized store-
operated Ca2+ entry channel component ORAI1 is not a regulator of vimentin expression 
induced by EGF in MDA-MB-468 breast cancer cells [5], but is a regulator of vimentin 
expression induced by fibroblast growth factor (FGF) isoform 4 in A549 and H1299 lung 
cancer cells [18]. A better understanding of the landscape of EMT induction, through the 
identification of the molecular players involved in Ca2+ signal dependent induction of vimentin, 
a classic mesenchymal marker, will provide new insights into this important process. 
 
The differential contribution of Ca2+ signaling to EMT induction with different stimuli is likely 
to be complex. Diversity of Ca2+ influx mechanisms is reflected in studies assessing store-
operated Ca2+ entry. The canonical pathway for the refilling of Ca2+ stores first involves the 
detection of Ca2+ store depletion by the endoplasmic reticulum Ca2+ sensor STIM1, followed 
by activation of Ca2+ influx via STIM1 interaction with ORAI1 hexameric Ca2+ channels [19, 
20]. However, in some cellular systems and/or stimuli, STIM1 can activate Ca2+ influx that is 
TRPC1-dependent, with possible differential contribution of ORAI1 [21-24]. Context 
dependent contributions of TRPC1 are reflected in the ability of TRPC1 silencing to attenuate 
phosphorylation of the transcription factor STAT3 induced by hypoxia but not EGF in MDA-
MB-468 breast cancer cells [25]. Despite the aforementioned studies, the potential contribution 
of STIM1, ORAI1 and TRPC1 in the regulation of vimentin induction associated with different 
mediators of EMT has not been fully explored. 
 
Buffering of increases in cytosolic Ca2+ ([Ca2+]CYT) with the fast Ca2+ buffer BAPTA-AM can 
attenuate both EGF- and hypoxia-induced vimentin expression in MDA-MB-468 breast cancer 
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cells [5]. However, these same studies observed a modest increase in basal vimentin expression 
by prolonged incubation with the slower intracellular Ca2+ buffer EGTA-AM. Intracellular 
EGTA is unable to buffer the highly localized increases in free Ca2+ that may occur near the 
mouth of Ca2+ channels upon their opening [26]. Numerous studies have reported the 
differential effects of BAPTA-AM and EGTA-AM on cellular events such as gene 
transcription [27-30]. However, the possible effect of EGTA-AM on vimentin expression has 
not been fully evaluated nor has the contribution of the Ca2+ signal or the molecular 
components involved in this type of EMT induction.  
 
In this study, the ability of EGTA-AM to induce EMT was assessed in MDA-MB-468 breast 
cancer cells. The molecular pathways involved in EGTA-AM-mediated induction of the 
mesenchymal EMT marker vimentin involved components that do not contribute to other 
inducers of EMT, including the inhibitor of actin polymerization, cytochalasin D. Our results 
also provide another example of the differential contribution of STIM1 to events regulated by 
ORAI1 and TRPC1, and identify that the STIM1 contribution is dependent on the context of 
the type of cellular stimuli in MDA-MB-468 breast cancer cells. 
 
Materials and Methods 
Cell culture and reagents 
MDA-MB-468 breast cancer cells were maintained in DMEM with high glucose (D6546; 
Sigma-Aldrich, St Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS, GE 
Healthcare) and 4 mM L-glutamine (25030; Life Technologies, Carlsbad, CA, USA). Cells 
were incubated at 37C with 5% CO2 in a humidified atmosphere. For studies assessing the 
effect of intracellular Ca2+ chelation, cytochalasin D (250255; Calbiochem) or thapsigargin 
(T9033; Sigma-Aldrich) on EMT marker expression, 2104 cells were plated in 96-well tissue 
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culture plates. After leaving cells to attach overnight, complete medium was replaced with 
serum-reduced medium (SRM, 0.5% FBS) for 24 h. For EGTA-AM studies, cells were 
incubated for 1 h with 100 M EGTA-AM (E1219; Invitrogen, Carlsbad, CA, USA) or DMSO 
control (0.2% v/v, Sigma-Aldrich), before medium was replaced with fresh SRM for the 
remainder of the experiment. Cytochalasin D and thapsigargin were used at a final 
concentration of 300 nM and 100 nM, respectively, or DMSO control (0.1%) and cells were 
treated for 24 h prior to protein and/or RNA isolation. For inhibitor studies, MDA-MB-468 
cells were cultured as described above, but were pre-treated for 1 h with Y-27632 (Y0503; 
Sigma-Aldrich) or YM58483 (Y4895; Sigma-Aldrich) at the concentrations indicated. 
Inhibitor treatment was maintained for 24 h prior to protein and/or RNA isolation. MDA-MB-
468 cell line authenticity was confirmed via STR profiling using the GenePrint 10 System 
(Promega, Madison, WI, USA) by the Queensland Institute of Medical Research Berghofer 
Medical Research Institute and cells routinely tested negative for mycoplasma (Lonza, Basel, 
Switzerland). 
 
Immunoblotting 
Total cellular protein was extracted using protein lysis buffer supplemented with protease and 
phosphatase inhibitors (Roche Applied Science, Penzburg, Germany) and immunoblotting was 
performed using a vimentin antibody (V6389; Sigma-Aldrich) at a dilution of 1:750. PVDF 
membranes were incubated with vimentin antibody overnight at 4˚C or for 1 h at room 
temperature with -actin (A5441; Sigma-Aldrich) at 1:10,000, as previously described [5]. 
Protein quantification was performed using the Quantity One Software “rolling-ball” method 
(Bio-Rad, Hercules, CA, USA) and protein band intensity normalized to the loading control 
(-actin).  
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Fluorescence Microscopy 
For F-actin immunostaining, MDA-MB-468 cells were plated at a density of 1.5104 cells/well 
in 96-well black-walled imaging plates (BD Biosciences, Franklin Lake, NJ, USA). After 
allowing cells to attach overnight, complete medium was replaced with SRM for 24 h. Cells 
were then treated with either EGTA-AM or cytochalasin D as described above for 6 h. Cells 
were washed in PBS containing Ca2+ and Mg2+ and fixed in PBS containing 4% 
paraformaldehyde, followed by permeabilization with PBS containing 0.1% Triton X-100 
(Sigma-Aldrich). Non-specific sites were blocked with blocking buffer for 1 h at room 
temperature in a humidified chamber. For F-actin staining, cells were incubated (20 min) with 
Alexa-Fluor 488-Phalloidin (A12379; Life Technologies) diluted 1:40 in PBS from the 
methanolic stock solution. Nuclei were stained with DAPI (D1306; Life Technologies) for 10 
min at room temperature, according to the manufacturer’s directions. Images were acquired 
with a Nikon Eclipse Ti epifluorescence microscope using a 20 objective.  
 
siRNA transfection 
For experiments assessing the effect of siRNA-mediated silencing of gene targets on EGTA-
AM, cytochalasin D or thapsigargin-induced vimentin protein, MDA-MB-468 cells were 
plated at a density of 6103 cells/well of a 96-well plate. After allowing cells to attach 
overnight, cells were cultured in the presence of siRNA-containing medium for 48 h, followed 
by 24 h in SRM. Cells were then cultured in EGTA-AM, cytochalasin D or thapsigargin as 
described above. DharmaFECT4 Transfection Reagent (0.1 L/well) (T2004; Dharmacon, 
Lafayette, CO, USA) was used to deliver siRNA particles according to the manufacturer’s 
protocol. The following Dharmacon ON-TARGETplus SMARTpool (consisting of four 
rationally designed siRNAs) siRNAs were used: Non-targeting (D-001810-10-05), ORAI1 (L-
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014998-00-0005), STIM1 (L-011785-00-0005) and TRPC1 (L-004191-00-0005). Silencing 
efficiency was assessed 48-72 h post siRNA transfection using real time RT-PCR. 
 
Real time RT-PCR 
RNA isolation, purification and preparation of cDNA were performed as previously described 
[5]. The following TaqManTM Gene Expression Assays (Applied Biosystems, Foster City, CA, 
USA) were used: CD24 (Hs02379687_s1), CD44 (Hs01075861_m1), CDH2 (N-cadherin; 
Hs00983062_m1), ORAI1 (Hs00385627_m1), SNAI1 (Snail; Hs00195591_m1), STIM1 
(Hs00162394_m1), Twist1 (Hs00361186_m1), vimentin (Hs00185584_m1). Real time RT-
PCR reactions were run using a StepOnePlus Real Time PCR System (Applied Biosystems) 
under universal cycling conditions. Eukaryotic 18S rRNA (4319413E; Applied Biosystems) 
served as a reference to enable relative quantification of target gene expression. Gene 
expression was analyzed using the comparative CT method as described previously [31]. 
 
Measurement of intracellular Ca2+ 
Measurement of thapsigargin-mediated changes in store-operated Ca2+ entry was performed by 
loading cells with 2 µM of the cell permeant intracellular calcium indicator Fluo-4, AM 
(F14201; ThermoFisher Scientific, Waltham, MA, USA) and imaging with a fluorometric 
imaging plate reader (FLIPRTETRA; Molecular Devices, San Jose, CA, USA) and the BD PBX 
no-wash Ca2+ assay kit (640175; BD Biosciences, Franklin Lakes, NJ, USA) as previously 
described [5], with the following change: thapsigargin (100 nM) was used to deplete 
endoplasmic reticulum calcium stores. Cells were treated with YM58483 for 15 min at room 
temperature prior to performing the Ca2+ assay and the inhibitor concentration was maintained 
throughout the experiment.  Store operated calcium entry was assessed via the Peak 2/Peak 1 
ratio, peak 1 refers to peak [Ca2+]CYT induced by the endoplasmic reticulum  calcium pump 
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inhibitor and peak 2 refers to peak [Ca2+]CYT during store operated calcium entry after re-
addition of extracellular Ca2+. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism (v6.05 for Windows). Details of 
statistical analyses are provided in the corresponding figure legends. 
 
Results 
Our first experiments were focused on further assessing the phenomenon whereby EGTA-AM 
may induce basal vimentin expression in MDA-MB-468 breast cancer cells. During this 
assessment, we found that EGTA-AM incubation consistently produced pronounced vimentin 
protein expression (Fig 1A) and mRNA induction of vimentin and other mesenchymal markers 
(N-cadherin, Twist, Snail and CD44/CD24 mRNA levels) (Fig 1B) in MDA-MB-468 breast 
cancer cells. EGTA-AM also produced a change in the morphology of MDA-MB-468 cells 
from an epithelial, cobblestone appearance, to a more spindle-like morphology with cortical 
actin changing to actin stress fibers (Fig 1C). Given this change in cell morphology, we 
explored the possible role of cell shape changes in the induction of EMT markers in this model 
by assessing the effects of the actin polymerization inhibitor cytochalasin D. Similar to EGTA-
AM, cytochalasin D induced vimentin expression and the induction of EMT mRNA markers 
in MDA-MB-468 breast cancer cells (Fig 1D&E). Low concentration cytochalasin D (300 nM) 
also induced a spindle morphology, although it produced a more localized F-actin distribution 
as indicated by phalloidin staining (Fig 1F). These results demonstrate that EMT markers in 
MDA-MB-468 cells can clearly be induced by physical cell shape changes (via cytoskeletal 
reorganization) as well as chemical signals. This study therefore sought to define the cellular 
signaling pathways responsible for these two distinct modes of EMT induction in the MDA-
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MB-468 breast cancer cell line model, with a specific focus on the mechanisms associated with 
induction of vimentin protein expression. 
 
Given that an important role of Rho kinase/ROCK signaling is regulation of the actin 
cytoskeleton [32, 33], we assessed the effect of the ROCK inhibitor Y-27632 on cytochalasin 
D treatment. Y-27632 was a potent inhibitor of cytochalasin D-induced vimentin expression in 
MDA-MB-468 breast cancer cells (Fig 2A). However, vimentin expression induced by EGTA-
AM was insensitive to Y-27632-mediated ROCK inhibition (Fig 2B) indicating that EGTA-
AM and cytochalasin D engage at least some distinct cellular signaling pathways that lead to 
increased vimentin expression. 
 
While both BAPTA-AM and EGTA-AM reduce global [Ca2+]CYT levels, due to its slower rate 
of calcium binding, EGTA-AM will not buffer Ca2+ near the mouth of Ca2+ channels [26]. 
Therefore, the ability of EGTA-AM to induce vimentin expression could be due to the presence 
of regions of localized high Ca2+ levels at the plasma membrane following opening of Ca2+ 
permeable plasmalemmal ion channels in response to reduced global [Ca2+]CYT. Increased Ca2+ 
influx could be driven by reduced endoplasmic reticulum Ca2+ levels in [Ca2+]CYT EGTA-AM 
buffered MDA-MB-468 cells. To assess this potential mechanism, components of the store-
operated Ca2+ entry pathway (the pathway responsible for endoplasmic Ca2+ store refilling in 
epithelial cells) were silenced, specifically the Ca2+ channel component ORAI1 and the 
endoplasmic reticulum Ca2+ store depletion sensor STIM1 (Fig 3A&B and supplementary Fig 
1A-D). ORAI1 and STIM1 silencing each in-part reduced EGTA-AM-induced vimentin 
expression (Fig 3C), suggesting that store-operated Ca2+ entry was a partial driver for vimentin 
induction under these conditions. Indeed, direct promotion of store-operated Ca2+ entry via the 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor thapsigargin produced a 
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pronounced increase in vimentin expression, which was abolished by silencing of the store-
operated Ca2+ entry components ORAI1 and STIM1 (Fig 3D). Supporting the involvement of 
a non-identical mechanism for cytochalasin D induced vimentin expression in this model, 
cytochalasin D induced vimentin expression was insensitive to ORAI1 silencing (Fig 3E). 
However, a Ca2+ store depletion mechanism seemed to also be involved, given that silencing 
of STIM1 significantly reduced vimentin induction by cytochalasin D (Fig 3E). We therefore 
sought to define what STIM1 activated Ca2+ influx pathway may be involved in cytochalasin 
D-induced vimentin expression in MDA-MB-468 breast cancer cells. 
 
Given the sensitivity of cytochalasin D-induced vimentin expression to STIM1 but not ORAI1 
silencing, and reports of STIM1 activation of TRPC1 in other cell types [22-24], we assessed 
the effects of TRPC1 siRNA in this model. TRPC1 silencing (Fig 4A and supplementary Fig 
1A-D) significantly reduced cytochalasin D-induced vimentin expression in MDA-MB-468 
breast cancer cells (Fig 4B), suggesting a STIM1-TRPC1 pathway that is independent of 
ORAI1. Like ORAI1 silencing, TRPC1 silencing also partially inhibited EGTA-AM-induced 
vimentin expression (Fig 4C), suggesting EGTA-AM activates both TRPC1 and ORAI1 
mechanisms of vimentin induction. Consistent with the promotion of store-operated Ca2+ entry 
by TRPC1 silencing in MDA-MB-468 breast cancer cells [34], TRPC1 silencing enhanced the 
ability of thapsigargin to promote vimentin expression in this model (Fig 4D). These results 
support differential mechanisms of Ca2+ entry to promote vimentin expression by different 
stimuli in MDA-MB-468 cells.  
 
The availability of pharmacological inhibitors of ORAI1-mediated store-operated Ca2+ entry 
allowed us to further assess this pathway in the context of thapsigargin-induced vimentin 
expression. We first assessed the store-operated Ca2+ entry inhibitor YM58483 [35, 36]. In 
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MDA-MB-468 breast cancer cells, YM58483 inhibited store-operated Ca2+ entry induced by 
thapsigargin with an IC50 of 0.35 M and with maximal inhibition achieved at 3 M (Fig 
5A&B). As expected, based on the effects of ORAI1 siRNA, pharmacological inhibition of 
store-operated Ca2+ entry with YM58483 almost completely abolished thapsigargin-induced 
vimentin expression in MDA-MB-468 breast cancer cells at concentrations of 3 M and above 
(Fig 6A). Consistent with the inability of ORAI1 silencing to inhibit cytochalasin D induced 
vimentin expression, YM58483 (3 or 10 M) did not inhibit vimentin expression induced by 
cytochalasin D (Fig 6B). Paradoxically, unlike ORAI1 and STIM1 siRNA treatments, 
YM58483 did not significantly reduce EGTA-AM-induced vimentin expression (Fig 6C), 
perhaps suggesting an immediate compensatory role for TRPC1 in this pathway that may be 
negated under conditions of more enduring interference (i.e. genetic versus pharmacologic 
inhibition).  
 
Discussion 
The ability of some cancer cells to adopt a more metastatic phenotype and/or acquire resistance 
to therapies through enhanced expression of multidrug resistance proteins is a significant 
contributor to cancer mortality [1, 2], and has been associated with EMT [37, 38]. Increased 
expression of vimentin, along with the remodeling of cellular adhesion proteins can occur in 
response to the milieu of signals (growth factors, acidification, hypoxia and physical stresses) 
in the tumor microenvironment [4]. The identification of the Ca2+ signal in the regulation of the 
conversion of some cancer cells to a more mesenchymal phenotype, implicates Ca2+ permeable 
ion channels as contributors to the remodeling of vimentin expression in response to various 
stimuli [5]. However, a global increase in [Ca2+]CYT levels per se is not sufficient to induce 
vimentin expression in MDA-MB-468 breast cancer cells [5]. Hence, specific stimuli must 
engage particular Ca2+ permeable ion channels to alter [Ca2+]CYT signaling in such a way as to 
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activate specific pathways. For example, TRPC1 silencing suppresses hypoxia mediated 
increases in EGFR phosphorylation without affecting changes induced by EGF in MDA-MB-
468 breast cancer cells [25]. The increasingly diverse array of ion channels implicated in EMT 
induction in a variety of different cancer models warrants a deeper understanding of how 
different EMT inducers engage different Ca2+ influx pathways, and which of these are 
indispensable to EMT induction.  
 
This study demonstrated the ability of the slow Ca2+ buffer EGTA-AM to induce vimentin 
expression via an ORAI1-dependent pathway in MDA-MB-468 breast cancer cells. This may 
be due to a reduction in endoplasmic reticulum Ca2+ levels, subsequent STIM1-mediated 
activation of ORAI1 and a local increase in Ca2+ at the plasma membrane near ORAI channels, 
which would not be buffered by EGTA-AM [26]. Such a mechanism is supported by the ability 
of STIM1 silencing to attenuate EGTA-AM-induced vimentin expression and the ability of the 
store-operated Ca2+ entry inducer thapsigargin to increase vimentin levels. This phenomenon 
is somewhat analogous to the selective activation of the Ca2+ dependent transcription factor 
NFAT1 by ORAI1 through Ca2+ increases near open ORAI1 channels [39].  Hence, localized 
calcium increases induced by ORAI1 activation may also be important in the induction of 
vimentin expression. 
 
Despite ORAI1 not being a regulator of EGF-induced vimentin expression in MDA-MB-468 
breast cancer cells [5], ORAI1-mediated Ca2+ influx is sufficient to promote vimentin 
expression. ORAI1 should therefore now be assessed in the context of other EMT inducers in 
this and other models. Our studies have also provided further evidence for the engagement of 
different cellular signaling pathways to promote vimentin expression through our comparison 
of vimentin expression induced by EGTA-AM and cytochalasin D. In contrast to EGTA-AM, 
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cytochalasin D-induced vimentin expression was sensitive to ROCK inhibition but was 
completely insensitive to ORAI1 silencing. However, the ability of STIM1 silencing to also 
attenuate cytochalasin D-induced vimentin expression was indicative of an endoplasmic Ca2+ 
store-dependent component, since STIM1 is an endoplasmic reticulum Ca2+ sensor. Our 
observation that TRPC1 silencing reduced cytochalasin D-induced vimentin expression is 
consistent with studies in other cell types that have shown that this ion channel can be a partner 
in STIM1-mediated events [21-24]. However, in contrast to reports in human umbilical vein 
endothelial cells and other models [40], TRPC1 does not contribute to store-operated Ca2+ entry 
in MDA-MB-468 breast cancer cells [34]. This lack of contribution of TRPC1 to store-operated 
Ca2+ entry in MDA-MB-468 breast cancer cells provides more evidence for the delineation 
between the signaling pathways induced by thapsigargin and cytochalasin D to promote 
vimentin expression in this model.  
 
Our studies also provide evidence that some stimuli may engage both TRPC1- and ORAI1-
dependent Ca2+ influx to induce vimentin expression. This is demonstrated by the ability of 
both ORAI1 and TRPC1 silencing to partially reduce vimentin expression induced by EGTA-
AM. Further studies are required to determine exactly how cytochalasin D and thapsigargin 
achieve specific activation of TRPC1 and ORAI1, respectively, in this model of breast cancer 
plasticity. However, possible mechanisms are (i) that the dramatic cytoskeletal and 
morphological remodeling induced by cytochalasin D drives different spatial localization of 
STIM1, which promotes distinct engagement with ORAI1 and TRPC1, and/or (ii) cytochalasin 
D induces other signaling pathways that drive a more TRPC1-dependent pathway. The inability 
of selective pharmacological inhibition of store-operated Ca2+ entry to inhibit cytochalasin D-
induced vimentin expression was expected since this mechanism of vimentin expression 
induction was also insensitive to ORAI1 silencing. Despite the ability of ORAI1 silencing to 
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also attenuate EGTA-AM-induced vimentin expression, this induction was insensitive to 
pharmacological inhibition of store-operated Ca2+ entry at concentrations of YM58483 that 
almost abolished thapsigargin-induced vimentin expression. The inability of YM58483 to 
inhibit EGTA-AM-induced vimentin expression may be due to TRPC1-dependent Ca2+ influx 
that may have compensated for the short-term pharmacological inhibition of ORAI1. 
Alternatively, it may be further evidence of a pathway involving STIM1-ORAI1 interactions 
that are independent of Ca2+ entry via the store-operated Ca2+ entry mechanism. Indeed, non-
canonical activation of ORAI channels has been reported in other models [41-43].  
 
Although ORAI1 and TRPC1 are clearly associated with vimentin induction by thapsigargin 
and cytochalasin D, respectively, in MDA-MB-468 breast cancer cells, these Ca2+ influx 
pathways may not regulate all EMT markers to the same extent. Indeed, the Ca2+ permeable 
ion channel TRPM7 regulates vimentin protein expression induced by EGF but not another 
EMT marker, Twist, in MDA-MB-468 breast cancer cells [5]. The nature of the stimuli 
therefore also determines which EMT markers are induced. In the complex in vivo tumor 
microenvironment, cancer cells are likely to simultaneously receive and process multiple 
microenvironmental cues (e.g., growth factor signaling, oxygen stress and mechanical cues), 
each of which may engage different signal transduction pathways to orchestrate a larger EMT 
program. Another major contributing factor may be the cell type. Cytochalasin D alone was 
not an inducer of vimentin expression in other EMT-sensitive cell lines that we examined 
(PMC42LA and A431, data not shown). This suggests that cytochalasin D induces EMT only 
when there is a specific interplay between the expression and localization of specific ion 
channels and cytochalasin D-induced changes in cell morphology and/or signaling. Hence, 
future studies should assess other models of EMT to define what features are important in this  
phenomenon. The heterogeneity in vimentin expression induction that we identified with 
 16 
different stimuli is summarized in Figure 7 and Table 1. This heterogeneity may represent a 
significant challenge in the therapeutic targeting of Ca2+ permeable ion channels for the control 
of metastatic progression and/or therapeutic resistance via EMT, if tumor microenvironmental 
factors also engage different Ca2+ permeable ion channels. Future studies should now focus on 
the identification of Ca2+ permeable ion channels for which pharmacological inhibition can 
individually or cooperatively suppress specific features of EMT across multiple stimuli and 
breast cancer models. 
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Figure legends 
 
Fig. 1 EGTA-AM and cytochalasin D treatment induce features of an EMT in MDA-MB-468 
breast cancer cells.  
MDA-MB-468 cells treated with (A) EGTA-AM (100 M, 1 h) or (D) cytochalasin D (cyto D, 
300 nM, 24 h) have elevated protein expression of the classic EMT marker vimentin at 24 h. 
Representative immunoblot and densitometric analysis (normalized to -actin). Relative 
mRNA levels of EMT-associated genes (vimentin, N-cadherin, CD44/CD24, Twist and Snail) 
following treatment of MDA-MB-468 cells with either (B) EGTA-AM (100 M, 1 h) or (E) 
cyto D (300 nM, 24 h) at 24 h. Bar graphs represent the mean  SD for three independent 
experiments. P<0.05 (unpaired t-test). Representative morphological changes in sub confluent 
MDA-MB-468 cells in response to treatment with either (C) EGTA-AM (100 M, 1 h) or (F) 
cyto D (300 nM, 6 h) at 6 h. DAPI nuclear stain (blue) and F-actin (green). Scale bar = 50 m. 
 
Fig. 2 Rho kinase/ROCK inhibition reduces cytochalasin D but not EGTA-AM induced 
vimentin expression.  
Representative immunoblot and densitometric analysis (normalized to -actin) of the effect of 
increasing concentrations of the Rho kinase/ROCK inhibitor, Y-27632 (0, 1, 10 and 25 µM), 
on (A) cytochalasin D (cyto D, 300 nM, 24 h) and (B) EGTA-AM (100 M, 1 h) induced 
vimentin protein expression at 24 h. Cells were pre-incubated with Y-27632 for 1 h prior to 
treatment with either EGTA-AM or cyto D, with Y-27632 maintained for the duration of the 
experiment. Bar graphs represent the mean  SD for three independent experiments. P<0.05 
(one-way ANOVA with Tukey’s multiple comparisons test). 
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Fig. 3 The major store-operated calcium entry components ORAI1 and STIM1, differentially 
regulate vimentin protein expression in MDA-MB-468 breast cancer cells induced by EGTA-
AM, cytochalasin D and thapsigargin.  
Analysis of percent remaining (A) ORAI1 and (B) STIM1 mRNA in MDA-MB-468 cells 
following siRNA-mediated silencing. Bar graphs represent the mean  SD for three 
independent experiments. P<0.05 (unpaired t-test). Representative immunoblot and 
densitometric analysis (normalized to -actin) of the effect of ORAI1 and STIM1 silencing on 
(C) EGTA-AM (100 M, 1 h), (D) thapsigargin (100 nM, 24 h) and (E) cytochalasin D (cyto 
D, 300 nM, 24 h) induced vimentin protein expression in MDA-MB-468 breast cancer cells at 
24 h. Bar graphs represent the mean  SD for three independent experiments. P<0.05 (one-way 
ANOVA with Tukey’s multiple comparisons test); NT, non-targeting. 
 
Fig. 4 TRPC1 silencing reduces cytochalasin D but not thapsigargin induced vimentin 
expression in MDA-MB-468 cells.  
(A) Analysis of percent remaining TRPC1 mRNA in MDA-MB-468 cells following siRNA-
mediated silencing (24 h). Bar graphs represent the mean  SD for three independent 
experiments. P<0.05 (unpaired t-test). Representative immunoblot showing the effect of 
TRPC1 siRNA-mediated silencing on (B) cytochalasin D (cyto D, 300 nM, 24 h), (C) EGTA-
AM (100 M, 1 h) and (D) thapsigargin (100 nM, 24 h) induced vimentin expression 
(normalized to -actin) in MDA-MB-468 breast cancer cells at 24 h. Bar graphs represent the 
mean  SD for three independent experiments. P<0.05 (one-way ANOVA with Tukey’s 
multiple comparisons test); NT, non-targeting. 
. 
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Fig. 5 YM58483-mediated pharmacological inhibition of store-operated calcium entry in 
MDA-MB-468 cells.  
(A) Average relative [Ca2+]CYT transients and (B) ratio of Peak 2/Peak 1 (maximum peak 
height, as indicated in panel (A)) in MDA-MB-468 cells pre-treated (15 min) with increasing 
concentrations of the store-operated Ca2+ entry inhibitor, YM58483. Inhibitor concentrations 
were maintained for the duration of the experiment (1200 s). Bar graphs represent the mean  
SD for three independent experiments. P<0.05 (one-way ANOVA with Tukey’s multiple 
comparisons test). 
 
Fig. 6 The selective store-operated calcium influx inhibitor YM58483 completely blocks 
thapsigargin but not EGTA-AM induced vimentin expression in MDA-MB-468 cells.  
Representative immunoblot and densitometric analysis of the effect of the store-operated Ca2+ 
influx inhibitor, YM58483, on (A) thapsigargin (100 nM), (B) cytochalasin D (cyto D, 300 
nM) and (C) EGTA-AM (100 M, 1 h) induced vimentin protein expression (24 h). MDA-
MB-468 cells were pre-treated for 1 h with inhibitor prior to treatment with either thapsigargin, 
cyto D or EGTA-AM and inhibitor was maintained for the duration of the experiment. Bar 
graphs represent the mean  SD for three independent experiments. P<0.05 (one-way ANOVA 
with Tukey’s multiple comparisons test). 
 
Fig. 7 Schematic representation of Ca2+-dependent pathways via which EGTA-AM, 
cytochalasin D and thapsigargin may act to induce vimentin expression in MDA-MB-468 cells. 
Blue box, ORAI1-dependent pathway; green box, STIM1-dependent pathway; red, TRPC1-
dependent pathway. 
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Table 1 Summary of the effect of siRNA-mediated silencing of store-operated Ca2+ entry 
components on EGTA-AM, cytochalasin D (cyto D) and thapsigargin-induced vimentin 
expression in MDA-MB-468 cells. Thapsigargin and cytochalasin D both use a STIM1-
dependent pathway for vimentin expression in MDA-MB-468 breast cancer cells but 
differentially engage ORAI1 and TRPC1. EGTA-AM-induced vimentin expression is STIM1, 
ORAI1 and TRPC1 sensitive. , increased; , decreased;  , no change, vimentin expression 
relative to non-targeting control. 
 
 
 
Table 1 
 siORAI1 siSTIM1 siTRPC1 
EGTA-AM    
Cyto D    
Thapsigargin    
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Supplementary Figure S1.  
Fig. S1 siRNA-mediated silencing of ORAI1 and STIM1 attenuate store-operated calcium 
entry, while TRPC1 modulates endoplasmic-reticulum Ca2+ release kinetics in MDA-MB-468 
cells. 
(A) Average relative [Ca2+]CYT transients, (B) peak 2 relative [Ca2+]CYT, (C) ratio of peak 
2/peak 1 (maximum peak height), and (D) time to peak 1 in MDA-MB-468 cells treated with 
siRNA targeting ORAI1, STIM1 or TRPC1. Graphs represent average values of 3 technical 
replicates (n=3 wells). NT, non-targeting. The phenotypes observed were consistent with those 
previously reported for the silencing of these proteins in this cell line (inhibition of store 
operated Ca2+ entry (ORAI1 & STIM1) and delay to reach peak [Ca2+]CYT (TRPC1) [1]. 
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Supplementary methods 
 
siRNA transfection 
For experiments assessing the effect of siRNA-mediated silencing of gene targets on store-
operated calcium entry, MDA-MB-468 cells were plated at a density of 6103 cells/well of a 
96-well plate. After allowing cells to attach overnight, cells were cultured in the presence of 
siRNA-containing SRM medium for 48 h, followed by 24 h in SRM. DharmaFECT4 
Transfection Reagent (0.1 L/well) (T2004; Dharmacon, Lafayette, CO, USA) was used to 
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deliver siRNA particles according to the manufacturer’s protocol. The following Dharmacon 
ON-TARGETplus SMARTpool (consisting of four rationally designed siRNAs) siRNAs were 
used: Non-targeting (D-001810-10-05), ORAI1 (L-014998-00-0005), STIM1 (L-011785-00-
0005) and TRPC1 (L-004191-00-0005).  
 
Measurement of intracellular Ca2+ 
Assessment of functional siRNA-mediated knockdown of ORAI1, STIM1 and TRPC1 in 
MDA-MB-468 cells was performed by loading cells with 2 µM of the cell permeant 
intracellular calcium indicator Fluo-4, AM (F14201; ThermoFisher Scientific) and imaging 
with a fluorometric imaging plate reader (FLIPRTETRA; Molecular Devices, San Jose, CA, 
USA) and the BD PBX no-wash Ca2+ assay kit (640175; BD Biosciences, Franklin Lakes, NJ, 
USA) as previously described [2]. 
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